{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:50:50Z","timestamp":1782143450201,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s41030-026-00363-0","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T11:52:40Z","timestamp":1779018760000},"page":"599-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes in Concurrent Cohorts of Elexacaftor\/Tezacaftor\/Ivacaftor (ELX\/TEZ\/IVA)-Treated versus ELX\/TEZ\/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19"],"prefix":"10.1007","volume":"12","author":[{"given":"Christian A.","family":"Merlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9738-8302","authenticated-orcid":false,"given":"Kate","family":"Van Brunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"8","key":"363_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","volume":"168","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"363_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024;10(1):53.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"363_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.JAA.0000515540.36581.92","volume":"30","author":"SD Brown","year":"2017","unstructured":"Brown SD, White R, Tobin P. Keep them breathing: cystic fibrosis pathophysiology, diagnosis, and treatment. Jaapa. 2017;30(5):23\u20137.","journal-title":"Jaapa"},{"key":"363_CR4","unstructured":"Cystic Fibrosis Foundation. 2024 patient registry annual data report. https:\/\/www.cff.org\/media\/38406\/download?inline. Accessed 5 Feb 2026."},{"issue":"11","key":"363_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/archdischild-2013-304400","volume":"99","author":"JC Davies","year":"2014","unstructured":"Davies JC, Ebdon AM, Orchard C. Recent advances in the management of cystic fibrosis. Arch Dis Child. 2014;99(11):1033\u20136.","journal-title":"Arch Dis Child"},{"issue":"17","key":"363_CR6","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L, et\u00a0al. VX-445-tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"key":"363_CR7","unstructured":"Vertex Incorporated. TRIKAFTA\u00ae (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf. Accessed 5 Feb 2026."},{"key":"363_CR8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202411-2231oc","author":"CL Daines","year":"2025","unstructured":"Daines CL, Polineni D, Tullis E, et\u00a0al. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3, open-label extension study. Am J Respir Crit Care Med. 2025. https:\/\/doi.org\/10.1164\/rccm.202411-2231oc.","journal-title":"Am J Respir Crit Care Med"},{"key":"363_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32597-8","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, et\u00a0al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/s0140-6736(19)32597-8.","journal-title":"Lancet"},{"issue":"9","key":"363_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry PJ, Mall MA, \u00c1lvarez A, et\u00a0al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385(9):815\u201325.","journal-title":"N Engl J Med"},{"issue":"19","key":"363_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et\u00a0al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"363_CR12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK, Volkova N, Ahluwalia N, et\u00a0al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J Cyst Fibros. 2023;22(4):730\u20137.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"363_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","volume":"22","author":"T Lee","year":"2023","unstructured":"Lee T, Sawicki GS, Altenburg J, et\u00a0al. Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis. J Cyst Fibros. 2023;22(3):402\u20136.","journal-title":"J Cyst Fibros"},{"issue":"18","key":"363_CR14","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Elexacaftor\/Ivacaftor\/Tezacaftor: first approval. Drugs. 2019;79(18):2001\u20137.","journal-title":"Drugs"},{"key":"363_CR15","unstructured":"Foundation CF. Cystic Fibrosis Patient Registry 2020 annual data report. https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Patient-Registry-Annual-Data-Report.pdf. Accessed 5 Feb 2026."},{"issue":"1","key":"363_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13052-021-00970-4","volume":"47","author":"AG Servidio","year":"2021","unstructured":"Servidio AG, Capata G, Levantino L, et\u00a0al. COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients. Ital J Pediatr. 2021;47(1):12.","journal-title":"Ital J Pediatr"},{"issue":"7","key":"363_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp EA, Fink AK, Goss CH, et\u00a0al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016;13(7):1173\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"363_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/joim.12197","volume":"275","author":"T St\u00fcrmer","year":"2014","unstructured":"St\u00fcrmer T, Wyss R, Glynn RJ, Brookhart MA. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570\u201380.","journal-title":"J Intern Med"},{"issue":"4","key":"363_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s41030-024-00269-9","volume":"10","author":"C Merlo","year":"2024","unstructured":"Merlo C, Thorat T, McGarry LJ, et\u00a0al. A retrospective, longitudinal registry study on the long-term durability of ivacaftor treatment in people with cystic fibrosis. Pulm Ther. 2024;10(4):483\u201394.","journal-title":"Pulm Ther"},{"issue":"25","key":"363_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"5","key":"363_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ppul.25250","volume":"56","author":"S Patel","year":"2021","unstructured":"Patel S, Thompson MD, Slaven JE, Sanders DB, Ren CL. Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic. Pediatr Pulmonol. 2021;56(5):1271\u20133.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"363_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jcf.2022.09.006","volume":"22","author":"M Doumit","year":"2023","unstructured":"Doumit M, Chuang S, Middleton P, et\u00a0al. Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic. J Cyst Fibros. 2023;22(3):581\u20136.","journal-title":"J Cyst Fibros"},{"key":"363_CR23","doi-asserted-by":"publisher","first-page":"1277457","DOI":"10.3389\/fpubh.2024.1277457","volume":"12","author":"M Liu","year":"2024","unstructured":"Liu M, Shi L, Yang M, et\u00a0al. Ecological comparison of six countries in two waves of COVID-19. Front Public Health. 2024;12:1277457.","journal-title":"Front Public Health"},{"issue":"4","key":"363_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41030-023-00241-z","volume":"9","author":"MS Schechter","year":"2023","unstructured":"Schechter MS, Sabater-Anaya N, Oster G, et\u00a0al. Impact of elexacaftor\/tezacaftor\/ivacaftor on healthcare resource utilization and associated costs among people with cystic fibrosis in the US: a retrospective claims analysis. Pulm Ther. 2023;9(4):479\u201398.","journal-title":"Pulm Ther"},{"issue":"1","key":"363_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7812\/TPP\/21.089","volume":"26","author":"E Walter","year":"2022","unstructured":"Walter E, Bass JL. The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use. Perm J. 2022;26(1):73\u20139.","journal-title":"Perm J"},{"key":"363_CR26","doi-asserted-by":"crossref","unstructured":"Konstan M, Lumsden B, Menon P, DerSarkissian M, Rice M. Clinical characteristics and outcomes of people with cystic fibrosis with homozygous minimal function genotypes: comparison to those with F508del\/minimal function genotypes. In: Poster and oral presentation at: North American Cystic Fibrosis Conference (NACFC) 2025. Seattle, WA. October 22\u201325, 2025. Abstract 728.","DOI":"10.1016\/S1569-1993(25)02344-6"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00363-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:24:23Z","timestamp":1782141863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00363-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00363-0","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christian A. Merlo reports consulting work for Vertex Pharmaceuticals Incorporated. Hela Romdhani, Maral DerSarkissian, and Aruna Muthukumar are employees of Analysis Group, which was contracted by Vertex Pharmaceuticals to perform the analyses. Lisa J. McGarry, Yiyue Lou, and Kate Van Brunt are employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in Vertex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol and other necessary documents were reviewed and approved by the Advarra Institutional Review Board (IRB) and the US CFFPR Protocol Review Committee before initiation of the analyses. Determination of exempt status was received in June 2022 by the IRB, and the study was approved by the US CFFPR Committee in January 2023. The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor, and followed generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE) and Good Research Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}